Amaninder
Friday, April 3, 2026
24.8
C
Bengaluru
Hot topics
Prabhir Jha: Digital is not just another technology, it is a mind-set
DigiStorm 2018 was held on 11 September at the...
Pharma GCCs – What Used to Happen in Boston or Basel Now Happens in Bangalore
GCCs - Indian Pharma moves up the Value Chain...
Rethinking Healthcare Communications for the Indian Context
Indian healthcare is sometimes an enigma: on one hand...
Patient Centered Pharma – Pipe Dream or Possible?
To me, patient centricity is as fascinating a concept as it is contradictory. It is fascinating because it puts power into the hands of the patient. And it is contradictory because pharma does not like giving away power over its messages or processes. Pharma has traditionally never enjoyed interaction and has depended on ‘pushing’ messages across rather than having ‘conversations’. It probably also explains why we make do with medical reps who are not the sharpest knives in the drawer and scarcely invest in sharpening them.
Can Indian Doctors and Patients Trust Generics Over Branded Generics? ...
The ongoing debate around branded versus generic medicines in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Hot topics
Glosing the Gender Gap
Guest Editorial by Sharadha Iyer on the urgent need to close the gender gap in the Indian Pharma Industry
Draft Pharma Policy
Get an in-depth view into the Draft Pharma Policy - MedicinMan does a deep dive with the President of Karnataka Drug and Pharmaceutical Manufacturers Association
FLUX – Indian Pharma in the Post VUCA World
Introduction
For decades, leaders and organizations have relied on the...
Track and Trace: Indian Pharma – Current and Future Applicability
Pharmaceutical companies must contend with challenges from supply chain lapses (theft, diversion, S.O.P. deviations, product recalls, reverse logistics etc.) counterfeiting and stringent regulations. These challenges get compounded when dealing across the states and country business operations, besides that not only impact tangible profits but also the intangible brand credibility. In this context, there is also a credible increase in public awareness about the genuineness of medicine (in particular medicine that require cold chain) and their predictability of clinical outcomes.
Providing visibility and full traceability becomes a paramount importance to both the Industry and the Govt. – A fool proof solution not only brings transparency in the system, but can also be a key differentiator, and undoubtedly can create immense opportunities for a competitive advantage.
Coughing All the Way to the Bank: The High Cost of India’s Booming Cough Syrup Market
India’s cough syrup market, worth over ₹21,800 crore in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Newsletter
Get important news delivered directly to your inbox and stay connected!